Optimization of preparation of curcumin-catanionic nanoparticles lipid carriers by central composite design-response surface methodology / 中草药

Objective: To optimize the formulation of curcumin-catanionic nanoparticles lipid carriers (Cur-CNLC) by central composite design-response surface methodology (CCD-RSM). Methods: Cur-CNLC were prepared by film dispersion-ultrasonic emulsifying method. A four factor, five-level central composite design was employed, with the solid lipid quality (X1), liquid lipid quality (X2), lecithin quality (X3), and mixed surfactant concentration (X4) as the independent variables. The dependent variables were the entrapment efficiency (Y1) and drug loading (Y2). The data were simulated using multi-linear equation and second-order polynomial equation, the possibly optimal formulation was predicted by response surface method. Results: The entrapment efficiency, drug loading, average particle size, polydispersity, and Zeta potential of the Cur-CNLCs prepared under the optimized conditions were (94.38 ± 2.67)%, (6.93 ± 0.39)%, (235.9 ± 9.6) nm, 0.272 ± 0.017, and (-28.40 ± 0.35) mV, respectively. The bias between the measured values and the predicted ones is less than 5%. Conclusion: The CCD-RSM is effective and suitable for optimizing the formulation of Cur-CNLC.

Pharmacokinetic study of a new chewing gum dextromethorphan delivery system / 南方医科大学学报

<p><b>OBJECTIVE</b>To establish an high-performance liquid chromatography (HPLC)-based method for analysis of the pharmacokinetics and relative bioavailability of dextromethorphan chewing gum tablets in rabbits.</p><p><b>METHODS</b>The pharmacokinetic parameters and the relative bioavailability of dextromethorphan chewing gum preparation in rabbits were compared with those of the commercially available chewing dextromethorphan tablets using 3P97 software.</p><p><b>RESULTS</b>Pharmacokinetic analysis of the new dextromethorphan chewing gum tablets showed a AUC of 488.76 ∓ 175.00 ng.ml(-1).h, C(max) of 95.45 ∓ 17.53 ng/ml, and t(max) of 1.83 ∓ 0.57 h as compared with the corresponding parameters of 370.13 ∓ 90.56 ng.ml(-1).h, 174.00 ∓ 47.88 ng.ml, and 1.04 ∓ 0.14 h for the commercially available chewing tablets. The relative bioavailability of the new chewing gum medicine system was (140.73 ∓ 65.91)%.</p><p><b>CONCLUSION</b>The new dextromethorphan chewing gum preparation shows an increased AUC((0→)), decreased C(max), and prolonged t(max) in comparison with the commercially available chewing tablets, with also a greatly enhanced relative bioavailability.</p>